The contraindications to ribavirin also apply to this combination regimen. Refer to the ribavirin prescribing information for a list of contraindications for ribavirin. TECHNIVIE is contraindicated: In patients with severe hepatic impairment (Child-Pugh C) due to risk of potential toxicity [see Use in Specific Populations and Clinical Pharmacology)]. With drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. With drugs that are moderate or strong inducers of CYP3A and may lead to reduced efficacy of TECHNIVIE. In patients with known hypersensitivity to ritonavir (e.g. toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome). lists drugs that are contraindicated with TECHNIVIE (see INTERACTIONS WITH OTHER MEDICINES). 4– Drugs that are contraindicated with TECHNIVIE Drug Drug(s) within Class that are Contraindicated Clinical Comments Alpha1-adrenoreceptor antagonist Alfuzosin HCl Potential for hypotension. Antianginal Ranolazine Potential for serious and/or life-threatening reactions Antiarrhythmics Amiodarone, quinidine Potential for cardiac arrhythmias. Dronedarone Potential for serious and/or life-threatening reactions such as cardiac arrhythmias Anticonvulsants Carbamazepine, phenytoin, phenobarbital Ombitasvir, paritaprevir and ritonavir exposures may decrease leading to a potential loss of therapeutic activity of TECHNIVIE. Antihistamines (for systemic use) Astemizole, terfenadine Potential for cardiac arrhythmias. Antigout medications Colchicine (in patients with renal or hepatic impairment) Potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment. Antimycobacterial Rifampicin Ombitasvir, paritaprevir and ritonavir exposures may decrease leading to a potential loss of therapeutic activity of TECHNIVIE. Antipsychotic Blonanserin No information on potential effects is currently available
Lurasidone Potential for serious and/or life-threatening reactions Ergot derivatives Ergotamine, dihydroergotamine, ergonovine, methylergonovine ergot toxicity characterised by vasospasm and tissue ischemia has been associated with of ritonavir and ergonovine, ergotamine, dihydroergotamine, or methylergonovine. products Ethinyl medications such as combined oral contraceptives Potential for ALT elevations [see Precautions]. GI motility agent Cisapride Potential for cardiac arrhythmias. Herbal product St. John’s Wort (Hypericum perforatum) Ombitasvir, paritaprevir and ritonavir exposures may decrease leading to a potential loss of therapeutic activity of TECHNIVIE. HMG-CoA reductase inhibitors Lovastatin, simvastatin, atorvastatin Potential for myopathy including rhabdomyolysis. Long acting agonist Salmeterol The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia. Neuroleptics Pimozide Potential for cardiac arrhythmias. Non-nucleoside reverse transcriptase inhibitor Efavirenz Co-administration of efavirenz based regimens with paritaprevir and ritonavir was poorly tolerated and resulted in liver enzyme elevations. Phosphodiesterase-5 (PDE5) inhibitor Sildenafil when as REVATIO for the treatment of pulmonary arterial hypertension (PAH) There is increased potential for adverse events such as visual disturbances, hypotension, priapism, and syncope. Platelet aggregation inhibitors excluding heparin Ticagrelor Increased potential for ticagrelor associated adverse events.